Organigram Global (OGI) Change in Accured Expenses (2018 - 2026)
Organigram Global (OGI) posted quarterly Change in Accured Expenses of -$13.6 million for Q1 2026, down 469.07% year-on-year from $3.7 million in Q1 2025, and up 17.26% on a QoQ basis from -$16.4 million in Q4 2025.
Organigram Global (OGI) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Change in Accured Expenses for 7 consecutive years, with -$13.6 million the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses fell 469.07% year-over-year to -$13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.7 million (down 1585.25% YoY) and the FY2021 annual result came in at $170000.0, changed N/A from the prior year.
- Change in Accured Expenses advanced to -$13.6 million in Q1 2026 per OGI's latest filing, from -$16.4 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for OGI reached as high as -$2.4 million in Q1 2025 and fell as low as -$16.4 million in Q4 2025.
- A 3-year average of -$10.2 million and a median of -$10.9 million in 2026 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2025 — Change in Accured Expenses plunged 98.59% — and 2026, when it plunged 469.07%.
- Year by year, Change in Accured Expenses stood at -$8.3 million in 2024, then tumbled by 98.59% to -$16.4 million in 2025, then advanced by 17.26% to -$13.6 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$13.6 million, -$16.4 million, and -$2.4 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Organigram Global | 121.15 Mn | 154.23 Mn | 28.97 Mn | -13.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.60 Mn |
| Mar 31, 2026 | -13.60 Mn |
| Dec 31, 2025 | -16.43 Mn |
| Dec 31, 2025 | -16.43 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Dec 31, 2024 | -8.27 Mn |
| Dec 31, 2024 | -8.27 Mn |
| May 31, 2021 | 4.38 Mn |
| May 31, 2021 | 4.38 Mn |
| Feb 28, 2021 | 3.87 Mn |
| Feb 28, 2021 | 3.87 Mn |
| Nov 30, 2020 | -322,000.00 |
| Nov 30, 2020 | -322,000.00 |
| May 31, 2020 | 10.89 Bn |
| May 31, 2020 | 10.89 Bn |
| Feb 29, 2020 | 15,458.00 |
| Feb 29, 2020 | 15,458.00 |
| May 31, 2019 | 6.27 Mn |
| May 31, 2019 | 6.27 Mn |